Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 380

Showing 1-25 of 380 citing articles:

Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Mengwei Li, Xiaowei Chi, Ying Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 394
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 209
Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments
Melissa A. Elafros, Henning Andersen, David Bennett, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 10, pp. 922-936
Open Access | Times Cited: 170
Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 167
Carbohydrate-based drugs launched during 2000−2021
Xin Cao, Xiaojing Du, Heng Jiao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 10, pp. 3783-3821
Open Access | Times Cited: 147
Insulin resistance and cardiovascular disease
Constantine E. Kosmas, Maria D. Bousvarou, Christina Kostara, et al.
Journal of International Medical Research (2023) Vol. 51, Iss. 3
Open Access | Times Cited: 122
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Jingyue Wang, Quanwei Wang, Xinyu Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 120
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano, Miriam Longo, Simona Signoriello, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
Dhruv Mahtta, David J. Ramsey, Michelle Lee, et al.
Diabetes Care (2022) Vol. 45, Iss. 2, pp. 372-380
Open Access | Times Cited: 88
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 80
Genomics and phenomics of body mass index reveals a complex disease network
Jie Huang, Jennifer E. Huffman, Yunfeng Huang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 76
SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 69
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Juan P. Frías, Stanley H. Hsia, Sarah Eyde, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 472-483
Closed Access | Times Cited: 64
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 54
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Xunzhe Yin, Xiangyu Guo, Zuojia Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2844-2844
Open Access | Times Cited: 46
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Matthew Anson, Sizheng Steven Zhao, Philip Austin, et al.
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1869-1881
Open Access | Times Cited: 44
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 33
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
Liliana Laranjo, Fernando Laņas, Marie Chan Sun, et al.
Global Heart (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 32
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 24
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang, Jui‐Yi Chen, Hsien‐Yi Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2427258-e2427258
Open Access | Times Cited: 19
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 16
Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study
Karen M. Wai, Kapil Mishra, Euna Koo, et al.
American Journal of Ophthalmology (2024) Vol. 265, pp. 39-47
Closed Access | Times Cited: 15
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
Riccardo De Giorgi, Ivan Koychev, Amanda Adler, et al.
EClinicalMedicine (2024) Vol. 74, pp. 102726-102726
Open Access | Times Cited: 15
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
Kariem El‐Boghdadly, Jugdeep Dhesi, Philippa Fabb, et al.
Anaesthesia (2025)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top